FDA advisors vote against effectiveness of Biogen’s ALS drug for rare and aggressive form of the disease – CNBC

by

  1. FDA advisors vote against effectiveness of Biogen’s ALS drug for rare and aggressive form of the disease CNBC
  2. Biogen ALS drug considered not effective by FDA advisory panel MarketWatch
  3. FDA advisory panel recommends conditional approval of Biogen’s drug for rare form of ALS STAT
  4. FDA advisors reject Biogen’s ALS drug for rare and aggressive form of the disease CNBC
  5. Shares of tech companies are trading lower amid overall market volatility after the Fed raised rates by 25 basis point. – NetApp (NASDAQ:NTAP), Zoom Video Comms (NASDAQ:ZM), Autodesk (NASDAQ:ADSK), Unity Software (NYSE:U), Datadog (NASDAQ:D Benzinga
  6. View Full Coverage on Google News

Read original article here

Leave a Comment